Trends in upstream and downstream process development for antibody manufacturing by Gronemeyer, Petra et al.
Bioengineering 2014, 1, 188-212; doi:10.3390/bioengineering1040188 
 
bioengineering 
ISSN 2306-5354 
www.mdpi.com/journal/bioengineering 
Review 
Trends in Upstream and Downstream Process Development for 
Antibody Manufacturing  
Petra Gronemeyer, Reinhard Ditz and Jochen Strube *  
Institute for Separation and Process Technology, Clausthal University of Technology, Leibnizstraße 15, 
D-38678 Clausthal-Zellerfeld, Germany; E-Mails: gronemeyer@itv.tu-clausthal.de (P.G.);  
ditz@itv.tu-clausthal.de (R.D.) 
* Author to whom correspondence should be addressed; E-Mail: strube@itv.tu-clausthal.de;  
Tel.: +49-5323-722200; Fax: +49-5323-723570. 
External Editor: Christoph Herwig 
Received: 1 August 2014; in revised form: 12 September 2014 / Accepted: 29 September 2014 /  
Published: 1 October 2014 
 
Abstract: A steady increase of product titers and the corresponding change in impurity 
composition represent a challenge for development and optimization of antibody 
production processes. Additionally, increasing demands on product quality result in higher 
complexity of processes and analytics, thereby increasing the costs for product work-up. 
Concentration and composition of impurities are critical for efficient process development. 
These impurities can show significant variations, which primarily depend on culture 
conditions. They have a major impact on the work-up strategy and costs. The resulting 
“bottleneck” in downstream processing requires new optimization, technology and 
development approaches. These include the optimization and adaptation of existing unit 
operations respective to the new separation task, the assessment of alternative separation 
technologies and the search for new methods in process development. This review presents 
an overview of existing methods for process optimization and integration and indicates 
new approaches for future developments. 
keywords: process development; upstream processing; downstream processing; process 
integration; host cell proteins 
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1. Introduction  
Due to their broad application range, monoclonal antibodies (mAb) are used worldwide in a variety 
of applications such as therapeutics or in diagnostics [1–3]. Increasing product demands in combination 
with a market introduction of biosimilars call for less and less expensive products in order to remain 
competitive [4]. The current rather expensive production processes need to be improved significantly. 
Innovation in technological development as well as production processes are to be pursued [1,4]. 
However, it is not only necessary to improve process development and implement new unit operations. 
The products themselves also need attention [4,5]. Improvements in antibody quality and the 
development of more efficient and more economic processes are required [4,5]. 
Significant progress has been achieved by optimization of upstream processing (USP) in the last 
two decades. Process efficiency, achievable cell densities and product titers could be increased 
enormously in cell culture processes [1,2,5–8] by developing recombinant technologies as well as 
media and process control strategies [1,2,6,7]. Today, antibody concentrations of 3–5 g/L are achieved 
routinely and some companies have attained up to 10–13 g/L in fed-batch processes [5,6,8]. Antibody 
titers of up to 25 g/L via modified perfusion have been reported as well [7,9]. 
Upstream titers depend mostly on biological limits (e.g., cell line or media optimization) and can be 
raised without an increase in costs. USP manufacturing processes which generate higher titers still take 
place in the same reactor set-ups like earlier processes of lower titers. Consequently, the processed volumes 
are the same but the amount of antibody is increased. This results in feed volumes which contain  
15–100 kg mAb/batch at titers of 5 g/L in 20–25 kL bioreactors instead of 5–10 kg mAb/batch [6,8]. 
These feed volumes enter the facilities of downstream processing (DSP) which were designed for 
much lower amounts of antibody. The equipment reaches its physical limits and therefore, its capacity 
limits, resulting in an increase of processing time, material consumption and costs. 
Consequently, upstream capacity can be increased without raising the costs whereas downstream 
capacity always scales at least linearly with costs due to its physical principles for separation. At low 
product titers, upstream manufacturing is more expensive than DSP but higher titers shift the main 
manufacturing costs from USP towards DSP [7,8,10,11] and lead to a non-linear increase of overall 
costs for the manufacturing process [10]. This problem is amplified by a change in type and concentration 
of impurities which emerge from process changes during product titer optimization [12–16]. These 
modifications of broth compositions are an additional challenge for the downstream processing. 
In search of a solution for this “downstream bottleneck”, new approaches of optimization strategies 
and technology development are necessary. Innovative technologies should increase the maximum 
capacity and allow the handling of high titer volumes.  
2. State of the Art in Process Development and Optimization 
The current manufacturing technology for antibodies can be divided in development and optimization 
of USP and DSP. The development of technological platforms was possible in process development 
and consequently in manufacturing [16]. Examples can be cell line selection, media optimization or 
harvesting methods on the USP side [2,17] or the optimization of individual unit operations on the 
DSP side [16,18,19]. The optimization of process and product analysis is also platform-based. This 
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standardization of development steps takes place inside the company and aims at a decrease of 
investment, time and development cost per antibody [2,8,16–19]. In addition, material purchase and 
storage, scale up, process transfer are simplified [2,8] and the number of potential unit operations is 
reduced [2,19]. One example for the development of a manufacturing platform is published by  
Vogel et al. (2012) [20]. It is applied on a blood coagulation factor and the authors include an outlook 
on necessary process changes for antibody manufacturing. 
Due to the intense time pressure in process development, high-throughput (HTP) methods are 
employed in early process development [21,22]. They permit running a large number of screening 
experiments in a very small scale and can be performed with minimal amounts of material. Large 
amounts of data are provided in a short period of time [21–25]. HTP methods are often combined with 
statistically planned experiments (Design of Experiments, DoE). In statistically planned experimental 
designs, several factors can be changed within one set of experiments. These experimental designs take 
into account the number and type of factors, already existing information and reliability of the results. 
Classical designs are full factorial, fractional factorial or response surface designs. By applying DoE,  
a small number of experiments is sufficient to determine the influence of several parameters and to 
identify the most significant ones. HTP methods and DoE are both applied in the development of 
upstream as well as downstream processing [21,26–32]. 
Furthermore, concepts of Quality by Design (QbD) in combination with HTP methods or DoE [33,34] 
are encouraged to be applied in process [35–38] and analytical development [33,34]. QbD is a 
manufacturing principle in which product quality is built into the manufacturing process by understanding 
the associated risks and including strategies to mitigate those risks during manufacture [35–38].  
The implementation of QbD shall lead to the development of more robust and efficient manufacturing 
processes of mAbs with increased clinical efficacy [36]. Horvath et al. (2010) [39] described a QbD-based 
optimization approach in cell culture technology. Harms et al. (2008) [40] as well as Abu-Absi et al. [41] 
published case studies on mapping design space for fermentation and cell culture. In DSP, Jiang et al. 
(2010) [35] described a case study on the application of QbD principles for hydrophobic interaction 
chromatography and Pathak et al. (2014) [34] as well as Michels et al. (2012) [33] published examples 
for QbD-based development of analytical methods for antibody aggregates and size heterogeneity. 
2.1. Process Development in Upstream Processing 
Process development and optimization in USP includes various parts: cell line development  
and engineering, cell clone selection, media and feed development, bioprocess development and  
scale up [5,9,42–44]. Reactor design, cell harvesting, process control and the corresponding analytics 
can be part of the optimization process as well [9,42,43]. These areas are optimized individually and 
focus on a robust generation of a high product titer, high productivity and defined quality [5,6,43]. 
Figure 1 schematically presents the different optimization areas and lists the most important 
parameters. Following process development, process characterization, process transfer and set up of a 
cGMP-production take place in combination with process validation [5]. 
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Figure 1. Optimization areas and parameters in upstream processing. 
 
2.1.1. Cell Line Development and Clone Selection  
In the course of cell line development, a company-internal selection of host cells, expression 
vectors, transfection and selection methods takes place. The selection of the expression system is 
determined by its ability to ensure a high productivity and defined quality criteria [5,25,43]. The 
expression system most commonly used for the production of monoclonal antibodies or recombinant 
proteins are Chinese Hamster Ovary (CHO) cells [5,8,9,43,45]. The first proteins produced by  
CHO-derived cell lines were recombinant interferons and tissue-type plasminogen activator (tPA) [25]. 
In 2010, approximately 70% of all recombinant proteins have been produced in CHO cells [5]. 
High productivity and posttranslational processing are the criteria for cell line selection after cell 
transfection. Other factors, such as growth behavior, stable production, cultivation in serum-free 
suspension media, adaptive behavior, amplification, clone selection and possible risk assessment are 
taken into account as well [5,43]. Li et al. (2010) [5] and Costa et al. (2010) [43] provide good overviews 
of current methods for optimizing expression vectors and transfection methods. Several methods for 
cell line optimization are employed prior to cell clone selection to improve and ensure product  
quality [5,44,46]. One important parameter of product quality is the reproducibility of the glycosylation 
profiles. These depend on the respective cell clone, medium and cultivation conditions [5,9,44,47]. 
Commonly used methods are RNAi and gene deletion technologies [48,49]. Other approaches in cell 
engineering help to avoid ammonium and lactate accumulation [50–52] and improve cell growth [53]. 
Codon optimization and various approaches for gene-amplification via different selection markers serve 
to optimize the cell line [44]. Further approaches include metabolic engineering or anti-apoptosis 
enhancements. Costa et al. (2010) provide additional resources on cell engineering and its aspects [43]. 
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The subsequent selection of the best suited cell clone is one of the most important steps of the 
upstream development process as variations in the production cell line during clinical development 
constitute a major process change. Such a change requires an additional proof of product comparability. 
The cell clones considered for final production have to fulfill the required product quality, 
processability and volumetric productivity [43,54]. Criteria for selection are: growth, cell-specific and 
volumetric productivity, glycosylation profiles, development of charge variants, aggregate formation, 
protein sequence heterogeneity and clone stability among others [5,54,55]. In addition, metabolic 
characteristics can be exploited for cell clone selection, as well as their stability, robustness, high 
viability and low lactate or ammonium generation. At the end, process performance in the bioreactor 
decides which clone will be used for production and which will be saved as a backup. Running this 
selection process in the shortest time possible presents a big challenge. Especially product quality, 
productivity, and the metabolic profiles of the cells strongly depend on cell culture conditions [5]. 
Transient gene expression (TGE) as another possibility of protein production should be mentioned 
at least briefly. TGE is used to produce recombinant proteins over a short period of time following a 
DNA transfer into single-cell suspension cultures. There is no need for genetic selection of transfected 
cells and therefore a lot of time is saved [25,56–58]. Today, TGE is applied as a screening-tool for drug 
development since only small doses of potential drugs are needed within a short amount of time [56]. 
IgG yields of 2–80 mg/L have routinely been achieved with this process [56,57] which can be 
increased of 250–300 mg/L [58]. For industrial purposes, transient gene expression is promising 
regarding its high time-savings in cell line development. For manufacturing processes, it is likely to be 
tried with low-dose proteins before an application for antibody-derived products will be attempted [25,57]. 
In this review, concepts of process optimization on a cellular level are described mostly on an 
academic level due a restricted publishing of industrial owned knowledge on process optimization 
strategies. In industrial process development, the optimization of media and process conditions is 
primarily used to create more cells and therefore more product. This resulted in processes of up to  
21 days’ cultivation time, increased viabilities and cell densities 10–15 times higher than in the 1980s [25].  
2.1.2. Media Development and Optimization  
Media optimization processes have led to progress in commercially available media over the last 
decades. Early cell culture media like Ham’s F10 or Dulbecco’s Modified Eagle Media were based on 
blood serum supplements. These include a complex mixture of unknown components. In the 1970s and 
1980s, many serum-free media were developed in order to provide better defined cultivation media like 
IMDM or CMRL medium. Further improvements eliminated all animal-derived components to avoid 
pathogen contaminations and thus resulting in chemically defined media [17,27,59,60].  
Media development is a key factor in improving productivity and growth behavior of cells but it 
also influences product quality [26]. Today, commercially available media present the basis for media 
development towards optimized conditions for a process using a specific cell line. The optimal blend 
of media components has to be solved individually due to the high diversity of cell lines, processes, 
media components, interactions of components and metabolic pathways. Effective media development 
depends strongly on the choice of optimization tools. The most common strategies are based on: 
component titration, media blending, spent media analysis and automated screening [26,59,61].  
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A combination of these methodologies provides the most rational way of media development. The 
development process itself includes a screening process to identify important components, followed by 
an optimization step and a verification of the process [59]. Standardization of these development 
approaches led to a platform-based media development [30]. 
Traditionally, media were developed by changing one factor at a time [26,27]. In order to reduce 
experimental efforts, DoE and high-throughput methods are applied in industrial development 
processes [30–32]. As an example, a top down approach is described by Ma et al. (2009) [62]. Media 
development needs to be optimized for each cell line individually but its establishment as a platform 
process in development leads only to an improvement of USP. There is still some potential for 
optimization which can be drawn upon, if necessary [5]. 
Approaches for feed media development include variations in the concentration of the basal 
medium, nutrient consumption [27,61,62], accumulation of impurities and a balance of cell growth and 
volumetric productivity [63]. Generally, methods for feed media optimization are the same as in basal 
media optimization, including the use of DoE [29]. 
2.1.3. Development of Process Strategies 
Continuous processes in USP are already well established for unstable products. Continuous  
by-product removal and nutrient addition extend the cultivation time. A short retention time of the 
product preserves the product quality. The major advantage consists in high cell number and high 
productivity in a small-sized bioreactor [64–68]. This process is more challenging regarding technique 
and sterility. It produces large harvest volumes and requires large media volumes than batch or  
fed-batch processes [65,67,68]. Perfusion processes are applied in biopharmaceutical production and 
can also be used for high density seed bioreactors and cell bank manufacturing [66,67]. Cell retention 
devices are of high importance for the removal of fermentation broth from the reactor [64,66–70]. 
They can be divided into filtration- and acceleration-based devices. In addition to effective cell 
retention, they have to be robust [64,67] and scalable [69]. Gravity-based cell settlers, spin filters, 
centrifuges, alternating tangential-flow filters, vortex-flow filters, acoustic settlers and hydrocyclones 
are commonly used in small scale applications [64,69] but only few of them can be adapted to a larger 
scale. Scalable devices are mostly based on filtration, gravity settling and centrifugation. Pollock et al. 
(2013) [68] provide an overview of industrially applied retention devices in continuous antibody 
manufacturing. Internal spin-filters are used in production volumes of up to 500 L, and external ones up 
to 1000 L. On a larger scale, mostly gravity settlers are used [68]. A comprehensive overview of principles 
of sedimentation, centrifugation and filtration as cell retention devices is provided by Henzler (2012) [71].  
Recent developments resulted in a new device, called the ATF System (Refine Technology) [7,66–69]. 
The system uses tangential flow filtration with an alternating cell broth flow direction. A diaphragm 
pump is used to alternate these directions without additional shear stress and a cycle time of about  
1 min. The back flush created by the alternated movement reduces possible fouling effects [66,67]. 
This system is easy to scale up and presents a possibility for single-use applications in USP [67,69].  
It is used to generate ultra-high-density cell cultures such as concentrated fed-batch and concentrated 
perfusion processes [69]. Cell densities up to 2.14 × 108 cells/mL [67] as well as product titer of up to 
25 g/L are reached [7]. 
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The choice of a fed-batch or continuous process depends mostly on product quality issues, existing 
facilities and experiences. The development and optimization concentrates on defining optimal operation 
parameters including among others temperature shifts, gas exchange, shear stress, transfection process, 
feeding strategy, duration of the cultivation and perfusion rate [2,17,23,65,72–74]. This part of 
development aims for high cell numbers, defined product quality, high titer und an extension of 
fermentation duration [17,73,74] and is mostly performed by use of DoE. The same criteria are valid 
for the choice of a bioreactor system.  
2.1.4. Optimization of Bioreactor Systems 
A new trend addresses an implementation of single-use bioreactor systems. They have the advantages 
of lower capital investment and operational costs, flexibility [75–77], improved production scheduling 
and higher process replication [75,76]. They are applicable for GMP manufacturing and available up to 
2000 L in scale [76,77]. Different designs of single-use reactors are available, such as wave, orbital 
shaken, pneumatically mixed and stirred tank bioreactors [75,77–80]. They eliminate the need for 
cleaning or sterilization and, thus, significantly reduce contamination rates [76,80]. One new bioreactor 
system, based on cylindrical or square-shaped vessels which are orbital shaken, distinguishes itself by 
high gas transfer rates through surface aeration and a working scale of up to 2500 L as a disposable 
reactor [25]. First descriptions and simulations of fluid motions in these vessels were published by 
Reclari et al. (2014) [81]. Other disposable bioreactors have been developed based on a bag concept [80]. 
They are used not only in research but also in manufacturing processes in mini- and mid-scale as well 
as seed trains in perfusion mode. However, there is still a lot of work to be done in optimizing disposable 
bioreactor systems, especially in terms of aeration and mixing [78,80]. Up to now, the scale is limited 
up to 2000 L–2500 L [25,76,77], the diversity of options is restricted, and there is a lack in 
standardization, instrumentation and some remaining performance issues. Furthermore, there is a 
shortage of a validation process concerning the nature, quantity and risk of leachables and extractables 
from the disposable plastics [76,79,80]. The bags can also bind media components thus, decreasing the 
process performance [80]. These problems are currently in focus of development activities. 
For similar production organisms and growth behavior, the development a generic harvest process [16], 
which consists mostly of a depth filtration or a centrifugation [2,16], could be attractive. Recently, 
depth filters have been shown to absorb soluble impurities, like proteins or DNA. An implementation 
of such a filter needs to be investigated in terms of a process integration [2]. Other developments 
include flocculation as a primary recovery step [16]. For products which are not completely compatible 
with the platform, additional development is necessary [16].  
All development and optimization approaches in USP provide an increase in monoclonal antibody 
concentration from 50 mg/L in 1986 to 5–20 g/L today [7,8,82]. In spite of these achievements, the 
focus of optimization often neglects the drawbacks of impurities. Impurities will only be considered if 
they are highly toxic or if changes in their metabolic routes result in a higher production of the desired 
product. Considerations regarding subsequent separation problems are carried out rarely [1,13]. 
  
Bioengineering 2014, 1 195 
 
 
2.2. Process Development in Downstream Processing 
DSP development focusses on yield and productivity as well as on purity and process capacities. An 
increase in separation efficiency of single unit operations is achieved by expansion of existing facilities 
and by optimization of existing and alternative processes [2]. New methods for process development 
are under investigation. These include the establishment of platform technologies, high-through-put 
methods with approaches based on QbD and DoE-based experimental optimizations [2,21,36]. 
Additionally, an integration of modeling and simulation of unit operations as well as the use of  
mini-plant facilities is applied in process development (see Figure 2). 
Figure 2. Optimization fields in downstream processing. 
 
Figure 3. Schematic manufacturing process of monoclonal antibodies from cell culture [84]. 
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Traditionally, monoclonal antibodies were purified by a sequence of different chromatographic and 
membrane-based operations [2,7,8,11,16,83,84]. A virus-inactivating operation, a filtration-based 
virus-reducing step and a final diafiltration have to be included [1,7,16,17,83,84]. Figure 3 represents a 
typical process for antibody purification. A selected number of these individual steps are discussed in 
more detail in the following sections.  
2.2.1. Chromatographic Separations  
After cell harvesting by centrifugation or filtration, a chromatographic separation unit is used to 
isolate antibodies from fermentation broth [2,8,16,18,84,85]. Protein A chromatography is one of the 
most important unit operations for antibody capturing [16,85,86]. It distinguishes itself by high 
selectivity towards IgG-type antibodies, high flow rate and capacity. The dynamic binding capacity 
ranges from 15–100 g mAb/L resin depending on antibody, flow rate and adsorbent [16,87,88]. The 
degree of purity is consistently higher than 95% [4,85,86,89]. Process-related impurities like HCP, 
DNA, media components and virus particles are removed [16,85,86]. One of the major advances in 
recent years of process development consists in a better integration of chromatography to the overall 
manufacturing process. Elution conditions of the initial Protein A capture step are adjusted to the 
following unit operation in order to enter a subsequent virus inactivation step or an ion exchange 
chromatography [16]. This eliminates any need for buffer exchange between these unit operations and 
it is one example for a successful integration of single separation operations during the last decades. 
Problems exist in form of Protein A leaching and non-specific binding of impurities like HCP and 
DNA. Leached Protein A reduces the binding capacity of Protein A chromatography and needs to be 
removed in subsequent purification steps [16,86,90]. The amount of bound impurities depends on  
the adsorbent, composition of cell culture harvest, column loading and washing conditions [16,86].  
Tarrant et al. (2012) [86] and Shukla et al. (2008) [85] published studies on HCP interacting with 
different Protein A matrices and the product. 
Cation exchange chromatography (CEX) presents an alternative to Protein A chromatography [7,16,88,89]. 
It requires a pH shift of the feed and a decrease of the conductivity before loading onto the column in 
order to optimize the dynamic binding capacity [7,16]. Older CEX processes distinguished themselves 
by a capacity of 20–30 g/L which cannot cope with new increasing product titers [7]. Optimizations of 
the resin resulted in capacities as high as 100 g/L at high flow rates und purity [88,89,91,92]. This 
technique can be used for antibodies with a basic isoelectric point [16]. Antibody variants, e.g., charge 
variants or aggregates, can be removed as well as most negatively charged impurities [16]. The costs of 
CEX are approximately one fifth of the costs for Protein A chromatography [7]. Synagis and Humira are 
two examples of commercially available mAbs which are purified by an application of CEX as capture 
step [7,88].  
Another alternative of Protein A chromatography are mimetic resins. The resins possess ligands 
which bind immunoglobulins (Ig) specifically and can potentially replace Protein A [90]. These can be 
Ig-binding proteins like protein G and L, synthetic ligands, bioengineered peptides [90,93–95] or 
Protein A like porous polymeric monoliths [95]. Different approaches of Protein A mimicking are 
described by El Khoury et al. (2013) [93], Qian et al. (2012) [96], Roque et al. (2005) [97] and Teng et al. 
(2000) [98], among others. 
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Subsequently, up to three chromatographic separations are applied in a classic manufacturing process. 
Ion exchange chromatography (IEC) is often used to reduce residual impurities including product 
variants, remaining HCP and DNA, leached Protein A, media components, endotoxins and virus from 
the cell line [16]. Anion as well as cation exchange chromatography can be run in flow-through or in 
bind-and-elute mode. They are often applied directly after Protein A Chromatography. Hydrophobic 
interaction chromatography (HIC) is complementary to ion exchange chromatography and Protein A and 
is mostly used as polishing step. In flow-through mode, HIC removes mostly aggregates, in bind-and-elute 
mode process- and product-related impurities [16]. These separations are significantly less expensive 
than Protein A chromatography but they are limited in capacity and throughput. Considering increasing 
product titers and new separation tasks, they have reached their limits [11,16,99]. Different optimization 
approaches regarding resins, operation modes or elution conditions are tested in order to avoid these 
limitations. 
Optimization of a chromatography step includes the design of improved ligands and matrices. These 
improvements may allow shorter residence times, higher flow rates [11,16,100] and longer life cycles. 
Future effort should be directed towards increased binding capacity at manufacturing scale, the number 
of cycles to process a harvested batch and the establishment of an intermediate washing step to  
remove remaining impurities [16,86]. Gagnon (2012) reviews different development trends regarding 
chromatography [4]. Another focus consists in connected processing including salt tolerant media or 
mixed-mode application [101–103]. To eliminate Protein A as the currently most expensive 
chromatographic step, lower-cost alternatives are under investigation. Possible alternatives are 
combinations of ion exchange and hydrophobic interaction chromatography [104]. 
2.2.2. Non-Chromatographic Separations  
Further trends in DSP address the development of non-chromatographic operations such as 
membrane-based procedures [4,11,105], aqueous two-phase extraction (ATPE) [99,106–108], 
precipitation [2,4,6,18], crystallization [109,110] or affinity alternatives [11]. This trend aims to reduce 
or even eliminate chromatographic operations. Non-chromatographic separations are in many cases 
proven in non-pharmaceutical processes with much higher feed volumes. Therefore, they are particularly 
useful for DSP now that higher titers are involved and greater amounts of buffer are required. These 
“low-tech” separation methods are good for high-volume feeds and rapidly remove a lot of liquid. This 
development may allow a reduction of costs, process time and yield losses. 
Membrane processes are one of the most important unit operations in biopharmaceutical processing. 
In USP, microfiltration membranes filtrate media, buffer and gases; in DSP they can be used as initial 
harvest operation for removal of biomass [16,105,111], particles prior to chromatographic operations 
and DNA from cell cultures [105]. Ultrafiltration membranes with a range of 1–100 nm are used to 
concentrate and diafilter biomolecules [16,105]. In order to ensure virus clearance, symmetric membranes 
are necessary with a narrow pore size distribution of 20–50 nm [105,111]. The separation mechanism 
is mainly based on molecular weight and to a lesser extent on shape and charge [16,105,112]. Other 
membranes frequently used are depth filters or high performance tangential flow membranes which 
can be neutral or charged [16,111]. Kumar et al. (2013) separated biomolecules based on their charge 
by charged ultrafiltration membranes [113,114]. 
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The former function of membranes as selective barrier for filtration is extended towards a selective 
adsorption of molecules to separate them according to their chemical behavior [2,102,105,115,116]. 
This relatively new development in membrane technology is called membrane chromatography [16,105,111]. 
These are symmetric microfiltration membranes functionalized with specific ligands attached directly 
to the convective membrane pores [16,105,111,117]. Diffusive pores are eliminated, mass transfer of 
biomolecules depends on convection and the binding capacity is largely independent of flow rates [16]. 
Significant advances have recently been made in developing high permeability and high capacity 
sterile filters by application of composite membranes. Membrane adsorbers are used for polishing 
applications to remove contaminants [105,111]. Viruses, endotoxins DNA, HCP and leached Protein A 
binds to the membrane at neutral to slightly basic pH and low conductivity [16]. Additionally, salt-tolerant 
membrane adsorbers have been developed for viral clearance as well as HIC membranes which have 
comparable dynamic binding capacities to conventional HIC resins [111]. Other development trends 
investigate the possibility to apply membrane adsorber in capture and purification of large biomolecules 
and will focus on new designs of structures for bind-and-elute processes [105]. Other fields in need of 
optimization concern flow distribution, membrane size distribution and thickness [16]. 
Research activities on aqueous two-phase extraction (ATPE) show potential applications of this 
process for separation of cells and undissolved components, of impurities and product. ATPE is 
considered a simple and low-cost technology compared to Protein A chromatography. It has 
advantages in scalability, can be applied in continuous processes and has a high capacity [99,106–108]. 
Unfortunately, there is still a limited understanding of molecular mechanisms of ATPE [118]. Other 
downsides are difficulties regarding its use as a platform step due to complex interactions of the 
multiple components involved. Another problem might be a sensitivity to feed stream variability [11]. 
In spite of this, strategies for ATPE design and process implementation are being developed [118] and 
already applied in purification processes of recombinant proteins [119].  
Precipitation can also be used for protein purification in industrial scale [106,120–122]. Current 
research indicates possible applications for product concentration and the separation of product and 
impurities. Volume limitations of the subsequent unit operation can be accommodated [120]. Membrane 
filtration removes the supernatant and is followed by dissolving the precipitate in a preferred buffer 
volume. This filtration process can be carried out either by dead-end filtration in lab-scale or by  
cross-flow filtration in industrial scale [4,123]. Centrifugation can be used as a substitute for  
filtration [4,120]. Another application of precipitation could be as a purification step before a capture 
by CEX. HCP and media components would be separated before a chromatographic capturing would 
take place [124]. Antibodies can be separated by either ammonium sulfate precipitation [4,121,125] or 
co-precipitation with negatively charged polymers [4]. Another possible application consists in a  
co-precipitation of several impurities with positively charged polymers. Those impurities include 
acidic HCP, DNA, and residual media components [4,120,126]. 
Crystallization is mostly applied in protein structure analysis and is already used as a cost effective 
and scalable purification procedure for small molecules [109,110]. Examples are the purification of 
low molecular weight substances like amino acids or industrial enzymes [11], like industrial lipase, or 
ovalbumin [109,110]. In insulin purification, crystallization is applied as polishing step benefitting 
formulation aspects of higher stability [109]. Its application in antibody purification is limited due to 
their size and heterogeneity [11]. A possible establishment in the purification process could be 
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performed inexpensively and with large volumes [110]. Crystallization would benefit formulation due 
to a higher stability of the final product in crystalline form [109]. It might be a suitable alternative to 
chromatography or ultra- and diafiltration [109,110]. However, this procedure is currently not ready 
for use. Only three recent studies presented potential µl-scale crystallization of whole antibodies [110] 
and Smejkal et al. (2013) [110] reported a successful crystallization of an IgG1-type antibody in a 
stirred L-scale. 
Other technologies for process development and integration include flocculation [106,127] and 
magnetic separations [11], among others. 
A successful integration of new technologies into a separation sequence requires a lot of time  
and effort in process development. New methods, e.g., high-throughput-screening and/or modeling 
approaches, may be able to improve the manufacturing process. A standardization of a new unit 
operation, resulting in a reliable and robust operation which can be applied to other products, may 
allow its use as potential platform technology. This platform should be able to reduce time and effort 
in DSP development of other products significantly [2,16,18,30]. 
3. Critical Parameters in Process Development 
Current separation technologies in antibody purification are designed for feeds of 2–5 g/L product 
concentration [6,8] which are routinely reached in generic fed-batch processes [128]. In USP, further 
optimizations are aiming to increase the product volumes significantly. Product concentrations of up to 
25 g/L were achieved by a two week long modified perfusion process of PER.C6® [7,9]. Product titers 
of above 5 g/L are going to exhaust existing capacities in DSP [2,7,18] and extensions of these 
capacities would shift the main costs of manufacturing towards DSP [7,8,10,11].  
An increased antibody titer upstream requires a higher amount of chromatography resin, buffer and 
membranes downstream and consequently, costs scale. Strube et al. (2012) [10] presented studies on 
cost distributions in downstream processing depending on product concentrations. They show the shift 
of production costs towards DSP and a possible increase of costs of the overall manufacturing process 
in case of higher titer in USP development in future processes. Based on the assumption of a constant 
spectrum of impurities, the overall cost of goods (COG) decrease with increasing product titers. In 
contrast, downstream costs dominate the overall production costs with increasing titer. Assuming a 
change in the composition of impurities with increasing titers due to optimizations of cultivation 
parameters [12–16], the costs of DSP are significantly higher [10]. Considering the trend towards 
further increasing product titers in future processes, a similar trend of increasing costs is expected for 
downstream processing [10,17,84]. 
Impurities in Biopharmaceutical Manufacturing 
Impurities generally consist of product and process related components as well as contaminants [129]. 
Product related components are molecular variants of the desired target molecule [129], precursors, 
degraded products [130,131], aggregates or product variants by different posttranslational  
modification [131,132]. They arise from production or during storage and possess different properties 
compared to the product regarding activity, efficacy or safety aspects. Process related impurities are 
cell components like host cell proteins (HCP) or DNA, chemical additives, residual media  
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components [15,129,133] or leachables like Protein A [15]. Residual media components or digested 
components include carbohydrates, amino acids, vitamins, salts and lipids, among others. Contaminants 
include all adventitiously introduced materials which are not part of the manufacturing process, such as 
(bio-) chemical materials or microbial species. They should be strictly avoided [129]. 
Especially, host cell proteins (HCP) are a main source of impurities. This complex group of 
proteins is defined by their broad variety of properties. HCP of one process differ significantly from 
each other in their molecular mass, isoelectric point, hydrophobicity and structure. They can easily be 
a challenge for product purification due to the changing level, composition and property distribution 
during a single fermentation process.  
Few studies have investigated problematic HCP and their removal in DSP. Pezzini et al. (2011) [101] 
monitored the fate of HCP through chromatographic operations. Low et al. (2007) [11] and Guiochon 
and Beaver (2011) [134] reported the HCP profiles in eluates from Protein A chromatography. 
Hogwood et al. (2013) [13] also reported the significant impact of harvest operations on the HCP 
profile. According to them, early DSP operations impact the HCP profile and the relative abundance of 
particular proteins throughout product purification.  
HCP compositions depend strongly on metabolic pathways which are characteristic for the chosen 
cell line and clone and result in a characteristic pattern of proteins [14]. Other pathways are changed in 
order to optimize metabolic production routes of the product and thereby, changing production routes 
of secondary metabolic products [14,135,136]. Their composition depends on several factors: host 
organism [14], cell clone [137], protein of interest [136], route of metabolic expression [14,135], 
viability [12,137], stage of cell culture, process conditions in fermentation and harvest conditions [12]. 
Tait et al. (2012) [12] demonstrated the impact of age and viability of the cell culture on HCP 
composition. During the fermentation, cells produce different proteins at the end than they do in the 
beginning. This is due to changes in the environment and their metabolism. Additionally, the amount 
of HCP increases significantly at a stage of decreasing viability. Process conditions influence the HCP 
profile, too. According to Jin et al. (2010) [14] the HCP level can change by a factor of 0.5–7 due to 
variations of temperature, aeration, feeding strategy, medium composition, cell culture duration and 
harvest conditions, among others. The results of Tait et al. (2012) [12] indicate that the time of harvest 
is crucial towards the resulting spectrum of impurities which enters the downstream processing. Along 
these results, it should be investigated if an earlier harvest results in an easier separable HCP spectrum. 
This can improve the overall process in spite of a potential loss of production time. 
The changes in levels of HCP, their composition and distribution of properties present a high 
optimization potential in bioprocess development. The high dependency of HCP profiles from different 
USP parameters is suitable as an optimization tool. By changing the focus of early upstream 
development, it is possible to reduce the HCP production or to influence its composition and improve 
DSP performance. By identification of unfavorable proteins in DSP, a screening for cell lines which 
produce HCP at lower levels would improve product purification [13].  
4. Trends in Process Development and Optimization Strategies 
Integration of different downstream operations will advance. An integration of ion exchange and 
hydrophobic interaction chromatography would, for example, permit the use of only one buffer system 
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for both operations [104]. Further trends in purification technology include other non-chromatographic 
processes like membrane adsorbers [102,105], crystallization [109,110], precipitation or aqueous  
two-phase separation [99,106–108]. Predictive biopharmaceutical process design will gain importance 
in process development as well. Possible applications will result in cost reduction and improve the 
success rate of commercial viability [138]. In DSP, rigorous modeling is already established. Other 
approaches are developed regarding USP needs. For example, Kontoravdi et al. (2013) [139] presented 
an approach to model scale up and glycosylation behavior in USP of mAbs.  
Another new approach consists in the application of quantitative structure–activity relationship 
(QSAR) modeling. Data analysis methods and statistics are applied to develop models that can 
accurately predict biological activities or properties of compounds based on their structures [140,141]. 
QSAR modeling might be able to predict the chromatographic separation of proteins [142]. One 
example was published by Buyel et al. (2013) [142]. They described the use of QSAR modeling to 
optimize chromatographic removal of tobacco host cell proteins in biopharmaceutical production.  
Transient gene expression might be another interesting option in future manufacturing processes. It 
has already been established in process development in screening steps for possible proteins of interest. 
Its establishment as a manufacturing technology is going to require more effort on product titer, cell 
number, ensuring product quality [56] and industrial acceptance [25] but its application has significant 
potential to save time and therefore costs. An established transfection/expression process might allow 
running production campaigns for a diversity of different recombinant proteins, including antibodies, 
using one facility and one host cell line. It is likely to be significantly faster and more flexible.  
Girard et al. (2002) [57] presented a successful transient transfection on a 100 L scale. 
The implementation of new separation technologies on an industrial scale will require significant 
investments in development, scale up and validation including associated risks. Therefore, they need to 
differentiate themselves by distinct increases in efficiency and cost reduction and should be evaluated 
carefully [8]. To reduce production volumes, the need for facility flexibility and faster turnarounds will 
increase. This can lead towards implementation of disposables in manufacturing [2,80], continuous 
processing [143,144] and dedicated but decentralized manufacturing concepts in containers [145].  
Advances in single-use technology lead to its increased implementation in biopharmaceutical 
production in order to lower capital and operational costs, increase production flexibility and enable a 
rapid set-up of bioprocessing and progressive manufacture of multiple products [77]. Today, single-use 
product lines include devices from storage bags to bioreactors resulting in the possibility for a complete 
single-use upstream process [77]. Trends in development address limits in scale and scarcity of 
standardization and validation as well as interactions between the plastic bags and process  
components [80]. The possibilities of leachables and extractables need to be worked on as well.  
In DSP, it has been difficult and expensive to implement a fully single-use process up to now [77,80]. 
Recent advances achieved product-dedicated fixed columns and fully disposable columns [80]. 
Disposable membrane cassettes seem to be an appropriate alternative to flow-through chromatography 
steps [80]. Membrane adsorption technologies, single-use moving bed, countercurrent chromatography 
and other chromatography methods are likely to be implemented as single-use in coming years [77]. 
The limit in scale of disposable technologies results in considerations of alternatives in process 
strategies for fed-batch processes. Continuous processing in mAb manufacturing is one trend to be 
considered in the coming years. Vogel et al. (2012) [20] published a development strategy for a 
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platform process based on continuous operations on a small scale including membrane adsorber for 
processing of complex biopharmaceuticals, however not antibodies. A transfer of this scheme to 
antibody purification would require membrane adsorber of a much higher capacity. Other options consist 
in the development of continuous operation modes of ATPE [107,146,147], centrifugation [148] or 
new continuous principles in chromatography, like MCSGP [149] or iCCC [150]. In upstream 
processing, continuous cultivations are already well established, as described before. Today, 
development trends concentrate on new cell retention devices and modifications of operation modes. 
The most interesting example in USP consists in a possible application of ATF as modified perfusion 
or concentrated fed-batch process [66,67,69]. In combination with continuous DSP and disposable 
technologies, it presents the opportunity to small-scale manufacturing processes of low investments 
costs and risks. In addition, the creation of high-volume cell banks could also be achieved resulting 
into a shortened bioreactor train in manufacturing processes [69]. 
In terms of capacity, it is most likely that current large facilities (>10,000 L) will remain. New 
capacities, however, will be added on a lower scale. Other products, for example individualized 
biologics and personalized medicines, will probably be produced in small scale using single-use 
technologies due to small required volumes. This trend is likely to advance towards modular facilities. 
Bioprocessing unit operations can be housed in container-like transportable clean rooms allowing the 
whole manufacturing process to be transported, constructed and operational within the shortest amount 
of time [77]. They also have the advantage of possible use in GMP-challenged countries. 
Current optimization approaches are aimed at single unit operations within the overall manufacturing 
process. Optimizations between USP and DSP currently focus on titer, aggregates and, if required, 
isoforms. Turbidity may be another parameter as well. DNA content is considered by choosing an 
appropriate harvest operation which reduces possible cell damage to a minimum. Other impurities are 
seldom taken into account during process development. This is going to be a problem since steadily 
increasing product titers involve creating impurities which are more difficult to separate. In order to 
optimize the overall manufacturing process, it is necessary to take these impurities into account. The 
question is: Would it be better to produce less product in order to change the impurity profile towards 
less impurities or at least to create only impurities which are easy to separate? Such a concept might 
result in a less expensive manufacturing process due to reduced yield losses. This integration of 
upstream and downstream processing can be considered a first useful tool. It addresses this challenge 
regarding HCP and changes the focus of upstream development. Foci of media and process 
optimization need to be adapted as well as new selection strategies for cell lines, and cell clones have 
to be implemented. Data by the groups of Hogwood (2013) [13] and Liu (2009) [151] suggested that 
such a change of early process development in USP focusing on HCP should seriously be considered. 
5. Concluding Remarks and Outlook 
Demands for high quality biologics will continue to increase in the coming decades. However, the 
boundary conditions will change substantially. Amounts to be produced and the number of products will 
increase. Additionally, there will be less, or even no blockbusters due to a shift towards stratified 
medicine. Many of the current blockbusters will be “running out of patent” during the next years.  
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In combination with increasing pressure from regulatory agencies for enhanced quality and lower 
process costs from the health care systems, we are facing a major challenge. 
The trend towards stratified therapeutics will support a change in plant design aiming for highly 
flexible multi-purpose facilities for small production volumes. Such a development will not only  
push innovation in the development of single-use technologies but also in the development of  
non-chromatographic, continuous and flexible downstream operations. As one consequence of these 
changes in process development, an integration of USP and DSP development regarding impurity 
profiles would be useful as a supporting tool for process optimization which can be established at 
reasonable expense. 
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